In a 53-year-old woman whose last menstrual period was 7 months ago, with hypertension treated with amlodipine, migraine with aura, bipolar disorder treated with olanzapine, BMI 28.1 kg/m², blood pressure 144/76 mm Hg, creatinine clearance 76 mL/min, and QTc 478 ms, what stage of the menopausal transition does she fall under according to the Stages of Reproductive Aging Workshop (STRAW) + 10 system?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 26, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

STRAW+10 Staging Classification

This patient is in the late menopausal transition (Stage -1).

Rationale for Stage Classification

According to the STRAW+10 staging system, the late menopausal transition (Stage -1) is defined by amenorrhea of ≥60 days but less than 12 months 1. This patient's last menstrual period was 7 months ago (approximately 210 days), which falls precisely within this window.

Key Distinguishing Features:

  • Stage -1 (Late Menopausal Transition): Amenorrhea ≥60 days to <12 months
  • Stage +1 (Early Post-menopause): Amenorrhea ≥12 months (menopause is clinically diagnosed after 12 consecutive months without menses) 1

The clinical diagnosis of menopause requires cessation of menses for at least 12 months in women with an intact uterus 1. Since this patient has only been amenorrheic for 7 months, she has not yet reached the postmenopausal stages.

Clinical Context

At 53 years of age with 7 months of amenorrhea, this patient is experiencing the expected progression through the menopausal transition. The guidelines emphasize that menopause is a clinical diagnosis based on menstrual cycle criteria, and laboratory testing (FSH, estradiol) is not necessary for diagnosis in women with intact uteri who have clear menstrual patterns 1.

Important Clinical Considerations for This Patient:

While the question focuses on staging, this patient's comorbidities warrant attention for future symptom management:

  • Migraine with aura is a contraindication to estrogen-containing hormone therapy
  • Prolonged QTc (478 ms) requires caution with certain medications
  • Hypertension is adequately controlled on amlodipine
  • BMI 28.1 kg/m² places her in the overweight category

The patient will transition to Stage +1 (early post-menopause) once she reaches 12 months of amenorrhea, at which point menopause will be formally diagnosed.

References

Guideline

treatment of symptoms of the menopause: an endocrine society clinical practice guideline.

The Journal of clinical endocrinology and metabolism, 2015

Related Questions

What evidence supports the use of amlodipine in elderly patients with hypertension and marked blood‑pressure variability?
How should I manage a patient on amlodipine 5 mg who has a blood pressure of 159/83 mm Hg?
What are the indications, dosing regimen, contraindications, and common adverse effects of amlodipine?
How to manage uncontrolled Hypertension (HTN) in a patient with Diabetes Mellitus (DM) on amlodipine, valsartan, and bisoprolol with elevated blood pressure?
In a 54-year-old African-American woman with blood pressure now around 130/80 mm Hg on amlodipine 2.5 mg daily (previously 138/84 mm Hg), should the amlodipine dose be increased to 5 mg?
Should emergency medical services (EMS) apply a pelvic binder (pelvic sheet) for a suspected hip fracture in an older adult patient?
Why would tesamorelin act differently in patients without HIV?
In a 52-year-old woman who is 1.5 years after her final menstrual period, which hormonal change is expected according to the Stages of Reproductive Aging Workshop (STRAW) + 10 classification?
What are the clinical signs of brainstem herniation?
For a 58-year-old postmenopausal woman concerned about venous thromboembolism, which hormone therapy was shown in the 2024 Swedish nationwide registry study to have no increased risk of VTE?
In a 55-year-old postmenopausal woman with an intact uterus who experiences intolerable mood effects and breakthrough bleeding on standard oral estrogen/progestin therapy, has well‑controlled hot flashes, and osteopenia, which alternative hormone therapy regimen is most appropriate?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.